IFT Annual Meeting & Food Expo In Brief

Cantox expert advises on claim support: FDA's "competent and reliable scientific evidence" standard for structure/function claims appears less rigorous than its "significant scientific agreement" requirement for authorized or qualified disease-risk reduction claims, but is not actually so, regulatory consultant Kathy Musa-Veloso says. "Don't be deceived by this competent and reliable scientific evidence standard," she said July 19 at the Institute of Food Technologists Annual Meeting & Food Expo in Chicago. "In our view, it's really just a synonym for significant scientific agreement." Musa-Veloso, associate director of Cantox's Food & Nutrition Group, said even though industry stakeholders are surprised at the European Food Safety Authority's rejection rate for proposed nutrient claims, most structure/function claims in the U.S. likewise would be rejected (1"The Tan Sheet" June 7, 2010). FDA does not require firms to submit their products' structure/function claims for approval and clearly some product claims on the market are not substantiated. "If the food industry wants to encapsulate bioactives and claim efficacy akin to pharmaceuticals, [regulators] are expecting the same level of scientific data - robust clinical studies - which for the most part, do not exist," Musa-Veloso added during a session on health claims

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

Makary Pledges To Uphold Gold Standard Science, But First Address Confuses Some US FDA Staff

 

Some employees were not impressed with FDA Commissioner Martin Makary's first speech to the agency staff, saying he did not seem to understand the agency's mission.

Are Bigger Ad Policy Changes Coming After US FDA’s Drug Promotion Office Hit Hard By Layoffs?

 
• By 

The loss of policy analyst, legal, project manager and social scientist positions has experts wondering if the Trump Administration is eyeing a broader effort to limit DTC advertising. The OPDP layoffs are expected to result in delayed reviews of promotional pieces.

Landmark Pilot Paves Way for Faster Drug Approvals In Africa

 

In a historic move for Africa, five products have been backed for approval via a pilot that tested a continental listing process.